Skip to main content
Triangle logo TriangleGet started

Biospecimen Collection (NCT06526299)

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease: a one-minute explainerNCT065262991 min

Biospecimen Collection trial for Metastatic Castration-Resistant Prostate Carcinoma (NCT06526299). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adult men with progressive metastatic castration-resistant prostate cancer after an androgen-receptor pathway inhibitor. A PSMA scan must show low average tumor uptake, with no qualifying PSMA-negative lesions. Prior PSMA radioligand therapy is excluded.

The idea: lutetium-177 PSMA-617 binds prostate-cancer cells and delivers DNA-damaging radiation. Patients receive up to six infusions on an intensified schedule. Scans and blood tests track response; researchers measure time until PSA progression or death.

This phase 2 study plans 51 patients. Angela Castellanos Rodriguez leads at Fred Hutch/University of Washington, Seattle; two US sites recruit.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.